Prime Medicine Statistics
Total Valuation
Prime Medicine has a market cap or net worth of $242.56 million. The enterprise value is $104.40 million.
Important Dates
The next estimated earnings date is Friday, May 9, 2025, before market open.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Prime Medicine has 127.66 million shares outstanding. The number of shares has increased by 30.37% in one year.
| Current Share Class | 127.66M |
| Shares Outstanding | 127.66M |
| Shares Change (YoY) | +30.37% |
| Shares Change (QoQ) | +9.32% |
| Owned by Insiders (%) | 19.97% |
| Owned by Institutions (%) | 41.43% |
| Float | 60.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 79.12 |
| Forward PS | 108.66 |
| PB Ratio | 1.66 |
| P/TBV Ratio | 1.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 35.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.58, with a Debt / Equity ratio of 0.27.
| Current Ratio | 5.58 |
| Quick Ratio | 5.02 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -136.88% and return on invested capital (ROIC) is -74.30%.
| Return on Equity (ROE) | -136.88% |
| Return on Assets (ROA) | -51.51% |
| Return on Invested Capital (ROIC) | -74.30% |
| Return on Capital Employed (ROCE) | -78.01% |
| Revenue Per Employee | $13,939 |
| Profits Per Employee | -$915,336 |
| Employee Count | 214 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.39% in the last 52 weeks. The beta is 1.85, so Prime Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 1.85 |
| 52-Week Price Change | -73.39% |
| 50-Day Moving Average | 2.46 |
| 200-Day Moving Average | 3.75 |
| Relative Strength Index (RSI) | 38.70 |
| Average Volume (20 Days) | 1,423,146 |
Short Selling Information
The latest short interest is 19.41 million, so 15.20% of the outstanding shares have been sold short.
| Short Interest | 19.41M |
| Short Previous Month | 18.04M |
| Short % of Shares Out | 15.20% |
| Short % of Float | 32.00% |
| Short Ratio (days to cover) | 14.73 |
Income Statement
In the last 12 months, Prime Medicine had revenue of $2.98 million and -$195.88 million in losses. Loss per share was -$1.65.
| Revenue | 2.98M |
| Gross Profit | -152.31M |
| Operating Income | -202.47M |
| Pretax Income | -217.55M |
| Net Income | -195.88M |
| EBITDA | -196.34M |
| EBIT | -202.47M |
| Loss Per Share | -$1.65 |
Full Income StatementBalance Sheet
The company has $190.44 million in cash and $40.79 million in debt, giving a net cash position of $149.65 million or $1.17 per share.
| Cash & Cash Equivalents | 190.44M |
| Total Debt | 40.79M |
| Net Cash | 149.65M |
| Net Cash Per Share | $1.17 |
| Equity (Book Value) | 153.15M |
| Book Value Per Share | 1.20 |
| Working Capital | 173.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$122.87 million and capital expenditures -$7.29 million, giving a free cash flow of -$130.16 million.
| Operating Cash Flow | -122.87M |
| Capital Expenditures | -7.29M |
| Free Cash Flow | -130.16M |
| FCF Per Share | -$1.02 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -6,787.36% |
| Pretax Margin | -6,566.61% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Prime Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.37% |
| Shareholder Yield | -30.37% |
| Earnings Yield | -77.10% |
| FCF Yield | -51.23% |
Analyst Forecast
The average price target for Prime Medicine is $13.25, which is 597.37% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.25 |
| Price Target Difference | 597.37% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 112.02% |
| EPS Growth Forecast (5Y) | -26.53% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prime Medicine has an Altman Z-Score of -2.21 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.21 |
| Piotroski F-Score | 2 |